Great Lakes Advisors LLC Buys Shares of 61,481 ANI Pharmaceuticals, Inc. $ANIP

Key Points

• Great Lakes Advisors initiated a position of 61,481 ANI Pharmaceuticals shares valued at approximately $5.1 million, while institutional investors collectively own 76.05% of the company.
• ANI Pharmaceuticals exceeded quarterly expectations, reporting $2.21 in adjusted EPS and $266.04 million in revenue; revenue increased 25.8% year over year.
• Analyst sentiment remains moderately bullish, with a consensus “Moderate Buy” rating and an average price target of $105.83, although several firms recently downgraded ratings or reduced targets. Shares opened at $78.02, near their 50- and 200-day moving averages.

Great Lakes Advisors LLC bought a new position in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 61,481 shares of the specialty pharmaceutical company's stock, valued at approximately $5,089,000. Great Lakes Advisors LLC owned 0.27% of ANI Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Arrowstreet Capital Limited Partnership bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at $32,992,000. Deutsche Bank AG bought a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at about $26,775,000. Balyasny Asset Management L.P. lifted its holdings in shares of ANI Pharmaceuticals by 2,785.7% during the 3rd quarter. Balyasny Asset Management L.P. now owns 286,149 shares of the specialty pharmaceutical company's stock valued at $26,211,000 after purchasing an additional 276,233 shares in the last quarter. Rubric Capital Management LP increased its stake in ANI Pharmaceuticals by 354.7% during the 2nd quarter. Rubric Capital Management LP now owns 257,669 shares of the specialty pharmaceutical company's stock worth $16,813,000 after purchasing an additional 200,998 shares in the last quarter. Finally, UBS Group AG increased its stake in ANI Pharmaceuticals by 45.8% during the 3rd quarter. UBS Group AG now owns 589,874 shares of the specialty pharmaceutical company's stock worth $54,032,000 after purchasing an additional 185,172 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

Insider Transactions at ANI Pharmaceuticals

In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 3,313 shares of the stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $86.00, for a total transaction of $284,918.00. Following the transaction, the chief financial officer owned 177,543 shares in the company, valued at $15,268,698. This trade represents a 1.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of ANI Pharmaceuticals stock in a transaction on Monday, August 10th. The stock was sold at an average price of $77.00, for a total value of $243,474.00. Following the sale, the senior vice president directly owned 75,534 shares of the company's stock, valued at $5,816,118. This represents a 4.02% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 18,987 shares of company stock worth $1,546,405 in the last ninety days. 8.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ANIP. Zacks Research cut ANI Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 14th. Weiss Ratings lowered ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Tuesday, August 11th. Guggenheim cut their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a research note on Monday, August 10th. Wall Street Zen downgraded ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Finally, Canaccord Genuity Group decreased their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research note on Monday, August 10th. Four equities research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat.com, ANI Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $105.83.

ANI Pharmaceuticals Price Performance

Shares of ANIP opened at $78.02 on Thursday. The company's 50-day moving average is $80.57 and its 200-day moving average is $78.94. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.91 and a quick ratio of 2.41. The firm has a market capitalization of $1.79 billion, a PE ratio of 16.81 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a fifty-two week low of $70.15 and a fifty-two week high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. ANI Pharmaceuticals's quarterly revenue was up 25.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Equities analysts forecast that ANI Pharmaceuticals, Inc. will post 7.83 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI's product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.

Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source